PHIO Stock Risk & Deep Value Analysis
Phio Pharmaceuticals Corp
Healthcare • Biotechnology
DVR Score
out of 10
The Bottom Line on PHIO
We analyzed Phio Pharmaceuticals Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PHIO through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
PHIO Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
High
Market Risk
High
About Phio Pharmaceuticals Corp (PHIO)
Sector
Healthcare
Industry
Biotechnology
Market Cap Category
small
Market Cap
$13.08M
PHIO Deep Value Analysis
PHIO Red Flags & Warning Signs
- âš
Negative or inconclusive PH-762 clinical trial results
- âš
Significant shareholder dilution via equity offerings
- âš
Inability to secure sufficient future funding
Unlock PHIO Red Flags & Risk Warnings
Create a free account to see the full analysis
PHIO Financial Health Metrics
Market Cap
$13.08M
PHIO Competitive Moat Analysis
Sign in to unlockMoat Rating
None
Moat Trend
Stable
Moat Sources
1 Identified
Currently, the moat is nascent, based solely on its proprietary sd-rxRNA platform and associated intellectual property. Its durability is entirely contingent on clinical success and the ability to differentiate from numerous other immuno-oncology approaches.
PHIO Competitive Moat Analysis
Sign up to see competitive advantages
PHIO Catalysts & Growth Drivers
Near-Term (0-6 months)
- •PH-762 Phase 1/2a clinical data updates (Estimated Q2/Q3 2026)
- •New financing round announcements
Medium-Term (6-18 months)
- •Strategic partnership or licensing deal for sd-rxRNA platform
- •Expansion of pipeline candidates into clinical trials
Long-Term (18+ months)
- •PH-762 advancement to pivotal Phase 2/3 trials
- •Broad validation of sd-rxRNA platform across multiple indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
PHIO Bull Case: What Could Go Right
- ✓
Definitive positive clinical trial results for PH-762
- ✓
Announcement of a strategic partnership or non-dilutive funding
- ✓
Extension of cash runway to beyond 18 months without excessive dilution
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.
